Medindia

X

ActiPatch(TM) Granted Market Clearance by the Food & Drug Administration in the Kingdom of Jordan

Wednesday, November 14, 2007 General News J E 4
Advertisement
FREDERICK, Md., Nov. 14 BioElectronicsCorporation, (OTC Pink Sheets: BIEL), announced today that the Jordan Food &Drug Administration has cleared ActiPatch for sale. The Company has initiatedshipments for both the retail and the medical professional markets into theKingdom.

"We are proud to announce another step for our Company in introducing thepain relief and healing benefits of ActiPatch to the international market. Weare working closely with Distinction Corporation and excited to include themin our growing list of distributors. I have every confidence that this newrelationship will bring not only success to our two companies in the Kingdomof Jordan, but also additional expansion into other Middles East markets,"said Andrew Whelan, President of BioElectronics Corporation.

Farid Tamini, President of Distinction Corporation, said, "With theapproval process behind us, we will quickly launch this wonderful product inthe Kingdom of Jordan. We are pleased to be working with BioElectronics.There is an air of enthusiasm for this unique drug free therapy that willsurely multiply as the medical professionals and patients experience thebenefits of ActiPatch."

About BioElectronics:

BioElectronics Corporation is the maker of ActiPatch. ActiPatch is adrug-free anti-inflammatory patch with an embedded battery operated microchipthat delivers weeks of continuous pulsed therapy for less than a dollar a day.The unique ActiPatch delivery system, using patented technology, provides acost-effective, patient friendly method to reduce soft tissue pain andswelling.

For more information visit http://www.bioelectronicscorp.com

Safe Harbor Statement:

This news release contains forward-looking statements related to futuregrowth and earnings opportunities. Such statements are based upon certainassumptions and assessments made by management of both companies in light ofcurrent conditions, expected future developments and other factors it believesto be appropriate. Actual results may differ as a result of factors over whichthe companies have no control.

SOURCE BioElectronics Corporation
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Merck Serono Exercises Option to Rigel's R763/AS70...
S
Ceregene Completes Enrollment of Phase 2 Clinical ...